In the clinical setting, we showed that increased CD70 RNA expression significantly deteriorates overall survival (OS) in early-stage SCLC patients, making it a suitable target for future biomarker studies and clinical trials. The gene discussed is CD70; the disease is small cell lung carcinoma.